tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Onco-Innovations Partners with Dalton Pharma for Nanoparticle Manufacturing

Story Highlights
  • Onco-Innovations partners with Dalton Pharma to produce nanoparticle formulation.
  • The initiative aims to support regulatory filings and GMP transition for clinical readiness.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Onco-Innovations Partners with Dalton Pharma for Nanoparticle Manufacturing

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Onco-Innovations Ltd. ( (TSE:ONCO) ).

Onco-Innovations Limited has partnered with Dalton Pharma Services to manufacture its proprietary nanoparticle formulation, PEO-b-PBz-CL, for preclinical animal studies. This initiative aims to optimize and scale up production to support regulatory filings and transition to Good Manufacturing Practice (GMP) manufacturing, enhancing Onco-Innovations’ pathway towards clinical readiness and strengthening its position in the oncology sector.

More about Onco-Innovations Ltd.

Onco-Innovations Limited is a Canadian-based company focused on cancer research and treatment, specializing in oncology. The company is dedicated to the prevention and treatment of cancer through pioneering research and innovative solutions, holding an exclusive worldwide license to patented technology targeting solid tumors.

Average Trading Volume: 83,872

Technical Sentiment Signal: Hold

For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1